Overall, our results provide new evidence that LUCAT1 exerts an oncogenic function, and the LUCAT1/NCL/MYC axis might be a potential prognostic marker and therapeutic target for CRC. This evidence concerns the gene LUCAT1 and colorectal carcinoma.